nerofe

Peptideexperimental

Clinical trial activity

5 trials · 3 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2013 (NCT01690741)

Timeline

2010s

Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Jan 1, 2017
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Alcohol sulfotransferaseINHIBITOR
SULT2A1 inhibitor
- Bile salt sulfotransferase (SULT2A1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)C[C@@H](NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](N)Cc1c[nH]c2ccccc12)C(C)O)C(C)O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)O

Mol. weight: 1897.22 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297308 ↗

Also known as

nerofe
nerofe
nerofe
tcapf, human
tumor-cells apoptosis factor, human

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05661201	Phase 1	Jan 31, 2023	Georgetown University, Immune System Key Ltd
NCT04365179	Phase 1	May 15, 2020	Immune System Key Ltd, University of Miami
NCT03634150	Phase 1/Phase 2 (Phase 2)	Aug 20, 2018	Immune System Key Ltd
NCT03059615	Phase 2	Apr 2, 2017	Immune System Key Ltd
NCT01690741	Phase 1	Dec 1, 2013	Immune System Key Ltd

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Immune System Key Ltd	For profit	5	4	2	2013
Georgetown University	Academic/Hospital	1	1	1	2023
University of Miami	Academic/Hospital	1	0	1	2020

3 organizations

Page 1 / 1